StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) stock

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)

Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%

Bicycle Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Bicycle Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$175.18M. For fiscal 2025 it was -$249.68M. The highest annual figure on record is -$1.42M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$249.68M–
FY2024Dec 31, 2024-$164.72M–
FY2023Dec 31, 2023-$60.63M–
FY2022Dec 31, 2022-$86.11M–
FY2021Dec 31, 2021-$14.79M–
FY2020Dec 31, 2020-$17.79M–
FY2019Dec 31, 2019-$28.61M–
FY2018Dec 31, 2018-$26.08M–
FY2017Dec 31, 2017-$1.42M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$40.30M–
Q2 FY2026Jun 30, 2026-$49.61M–
Q1 FY2026Mar 31, 2026-$65.93M–
Q4 FY2025Dec 31, 2025-$19.35M–
Q3 FY2025Sep 30, 2025-$71.17M–
Q2 FY2025Jun 30, 2025-$72.79M–
Q1 FY2025Mar 31, 2025-$86.37M–
Q4 FY2024Dec 31, 2024-$9.40M–
Q3 FY2024Sep 30, 2024-$39.83M–
Q2 FY2024Jun 30, 2024-$44.63M-230.9%
Q1 FY2024Mar 31, 2024-$70.87M–
Q4 FY2023Dec 31, 2023-$47.29M–
Q3 FY2023Sep 30, 2023-$1.03M–
Q2 FY2023Jun 30, 2023$34.10M–
Q1 FY2023Mar 31, 2023-$46.41M–
Q4 FY2022Dec 31, 2022-$30.31M–
Q3 FY2022Sep 30, 2022-$5.87M-127.0%
Q2 FY2022Jun 30, 2022-$23.53M–
Q1 FY2022Mar 31, 2022-$26.40M–
Q4 FY2021Dec 31, 2021-$10.44M–
Q3 FY2021Sep 30, 2021$21.72M–
Q2 FY2021Jun 30, 2021-$12.37M–
Q1 FY2021Mar 31, 2021-$13.71M-164.8%
Q4 FY2020Dec 31, 2020-$16.62M–
Q3 FY2020Sep 30, 2020-$9.99M–
Q2 FY2020Jun 30, 2020-$12.35M–
Q1 FY2020Mar 31, 2020$21.16M–
Q4 FY2019Dec 31, 2019-$4.92M–
Q3 FY2019Sep 30, 2019-$10.89M–
Q2 FY2019Jun 30, 2019-$7.61M–
Q1 FY2019Mar 31, 2019-$5.20M–
Q4 FY2018Dec 31, 2018-$8.85M–
Q3 FY2018Sep 30, 2018-$4.66M–

More Bicycle Therapeutics figures

See a number that looks wrong?